ArticlePharmaceutics2013
The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer.
Article in Pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Targeted Enrichment of Engineered Bacteria on Triple-Negative Breast Cancer Turns Immunologically Cold Tumors Hot.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Tumor microenvironment-responsive nanoformulations for breast cancer.Discover nano · 2024Review
- The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date).Discover nano · 2024Review
- CD8Molecular medicine reports · 2024Article
- Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer.Pharmaceutics · 2023Review
- Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).Pharmaceuticals (Basel, Switzerland) · 2022Review
- Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review.Current drug metabolism · 2022Review
- Identification of Cancer-Associated Fibroblast Subtype of Triple-Negative Breast Cancer.Journal of oncology · 2022Article
- Immunotherapy for Triple-Negative Breast Cancer.Pharmaceutics · 2021Review
- Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1International journal of molecular sciences · 2021Article
- Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment.Pharmaceutics · 2021Review
- A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer.Frontiers in cell and developmental biology · 2021Article
- A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.Frontiers in immunology · 2021Article
- pH-Sensitive Co-Adsorption/Release of Doxorubicin and Paclitaxel by Carbon Nanotube, Fullerene, and Graphene Oxide in Combination withBiomolecules · 2018Article
- SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer.Breast cancer (Dove Medical Press) · 2017Article
- Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.Biomaterials · 2016Article
- Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Triple Negative Breast Cancer, TNBC, a highly aggressive and metastatic type of breast cancer, is characterized by loss of expression of the estrogen receptor (ER), progesterone receptor (PR), and a lack of overexpression of the human epidermal growth factor receptor 2 (HER2). It is a heterogeneous group of tumors with diverse histology, molecular uniqueness and response to treatment. Unfortunately, TNBC patients do not benefit from current anti-HER2 or hormone positive targeted breast cancer treatments; consequently, these patients rely primarily on chemotherapy. However, the 5-year survival rate for woman with metastatic TNBC is less than 30%. As a result of ineffective treatments, TNBC tumors often progress to metastatic lesions in the brain and lung. Brain metastases of invasive breast cancer are associated with 1 and 2 year survival rate of 20% and <2% respectively. Because the only current systemic treatment for TNBC is chemotherapy, alternative targeted therapies are urgently needed to improve the prognosis for TNBC patients. This review is focused on opportunities for developing new approaches for filling the current void in an effective treatment for TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.